Health Economics›Peripheral T-cell lymphoma›Relapsed or refractory randomized data

Relapsed or refractory randomized data

Peripheral T-cell lymphoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bendamustine monotherapy Variant #01	—	R 7 084	—	~16.5 mo	—	~8	~R 56 672 PFS proxy · indirect	2
GDP Variant #01	—	R 4 133	21d	—	—	~6	~R 24 796 indirect	—
DHAP Variant #01	—	R 2 495	28d	—	—	~2	~R 4 991 indirect	—
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	—	~7	~R 11 705 PFS proxy · indirect	1
Pralatrexate monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	1
Romidepsin monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	1

6 of 6 regimens shown